PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
PHI applies for listing on OTCQB in the United States
PHI is pursuing a dual listing on the US-based OTCQB Venture Market to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.
PostNews: Interim Report
Interim Report 4 2023/24
This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
PostNews
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
PostNews: Press Release
PHI bolsters Nordic sales presence with new distribution agreement between Altium and Kem-En-Tec Nordic
PHI is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem-En-Tec Nordic, a lab supplier dedicated to supporting BioScience labs in Denmark, Sweden, Norway, Finland and Iceland.
PostNews: Press Release
PHI expands to Spanish and Portuguese markets through Altium’s new subcontract with Paralab
PHI is pleased to announce a strategic expansion into the Spanish and Portuguese markets, facilitated by a new subcontract between its global distribution partner, Altium, and Paralab.
PostNews: Press Release
PHI partners with University College London to use HoloMonitor in a first clinical research project
PHI is excited to announce a strategic partnership with University College London (UCL). Under this collaboration, PHI will lend a HoloMonitor® M4FL system for use in an ongoing research project at UCL, which runs alongside a clinical trial. This partnership represents PHI’s first direct step in a hospital setting to explore the clinical applications of its innovative technology.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
National Institutes of Health Purchase HoloMonitor
Using HoloMonitor’s unique capability to non-invasively image and quantify cellular behavior over long time periods, scientists at the National Institute of Aging aim to understand how the heart’s “brain cells” contribute to aging.
New CEO commentary: “Understanding Skin Cancer”
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.
